Payment overview · 2025
General Payments
$361.52
19 reported records · 12 companies
Healthcare provider profile · identity verified
Aedra D. Andrade, MD
Allopathic & Osteopathic Physicians|Family Medicine · GALLUP, NM · NPI 1164435673
Verified facts
What the public records show
CMS Open Payments records show Aedra D. Andrade, MD received $361.52 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.37 | 14.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.83 | 12.7% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $42.52 | 11.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.27 | 10.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.12 | 10.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.82 | 9.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.22 | 9.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.86 | 5.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.35 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.17 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.09 | 4.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.90 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.52 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $35.82 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 112 |
| Lisinopril | Lisinopril | 364 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 57 |
| Gabapentin | Gabapentin | 229 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 43 |
| Losartan Potassium | Losartan Potassium | 158 | 46 |
| Omeprazole | Omeprazole | 152 | 36 |
| Simvastatin | Simvastatin | 146 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 55 |
| Furosemide | Furosemide | 131 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 36 |
| Metformin Hcl Er | Metformin Hcl | 99 | 29 |
| Metformin Hcl | Metformin Hcl | 98 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 28 |
| Bupropion Xl | Bupropion Hcl | 88 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 15 |
| Pregabalin | Pregabalin | 69 | 14 |
| Montelukast Sodium | Montelukast Sodium | 66 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Glimepiride | Glimepiride | 63 | 18 |
| Tramadol Hcl | Tramadol Hcl | 61 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 12 |
| Eliquis | Apixaban | 58 | 14 |
| Famotidine | Famotidine | 54 | 19 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 15 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Baclofen | Baclofen | 46 | suppressed |
| Fentanyl | Fentanyl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 18 |
| Potassium Chloride | Potassium Chloride | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Estradiol | Estradiol | 40 | 16 |
| Finasteride | Finasteride | 40 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 15 |
| Carvedilol | Carvedilol | 37 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Novolog Flexpen | Insulin Aspart | 33 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Prednisone | Prednisone | 32 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Tacrolimus | Tacrolimus | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Firdapse | Amifampridine Phosphate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.52 · 19 records | Lilly USA, LLC | BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE, GVOKE HYPOPEN, LEQVIO, Ohtuvayre, QULIPTA, REXULTI, SPRAVATO, TRINTELLIX, UBRELVY, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error